Conclusions Study -level data from this systemic review establish that different lipid lowering agents can lead to discordance between LDL-P and LDL-C , therefore , basing LDL-lowering therapy only on the achievement of cholesterol goals may result in a treatment gap .
Therefore , the use of LDL-P for monitoring lipid-lowering therapy , particularly for statins , can provide a more accurate assessment of residual cardiovascular risk
Purpose This systematic review was performed to summarize published experience using low density lipoprotein particle number ( LDL-P ) to monitor the efficacy of  lipid-lowering pharmacotherapies .
Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy
4The aim of this study was to evaluate changes in lipid profiles in patients with type 2 diabetes after treatment conversion from rosiglitazone to pioglitazone  while maintaining stable statin and other lipid-altering therapies . A total of 305 patients were enrolled in this open-label study . Patients had been taking stable dosages of rosiglitazone and statins for > 90 days . At baseline , patients discontinued rosiglitazone and started pioglitazone 30 mg/day , but continued statins and other lipid-altering therapies . The primary end point was change from baseline in fasting triglyceride levels . At 17 weeks after treatment conversion , patients had significant reductions in triglycerides ( -15.2 % ) , total cholesterol ( -9.0 % ) , and low-density lipoprotein ( LDL ) particle concentration ( -189 nmol/L ) , and increases in LDL cholesterol ( + 2.2 % ) , high-density lipoprotein ( HDL ) cholesterol ( + 1.8 % ) , and LDL particle diameter ( + 0.23 nm ) . In conclusion , after treatment conversion from rosiglitazone to pioglitazone while maintaining stable statin therapy , patients with type 2 diabetes had marked improvements in lipid profiles along with stable glycaemic control
Conclusions Study -level data from this systemic review establish that different lipid lowering agents can lead to discordance between LDL-P and LDL-C , therefore , basing LDL-lowering therapy only on the achievement of cholesterol goals may result in a treatment gap .
Therefore , the use of LDL-P for monitoring lipid-lowering therapy , particularly for statins , can provide a more accurate assessment of residual cardiovascular risk
Purpose This systematic review was performed to summarize published experience using low density lipoprotein particle number ( LDL-P ) to monitor the efficacy of  lipid-lowering pharmacotherapies .